Evidence map›Paper›PMID 41404791›Full record

ReviewBiophysical journal2025

Alpha-synuclein fibril structures cluster into distinct classes.

Moses H Milchberg, Owen A Warmuth, Collin G Borcik, Dhruva D Dhavale, Elizabeth R Wright, Paul T Kotzbauer, Chad M Rienstra

Abstract readReview
In one paragraph

Review in Biophysical journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Reverse-engineering amyloid strains with generative protein design.bioRxiv : the preprint server for biology · 2026
    Article
  5. bioRxiv : the preprint server for biology · 2026
    Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Moses H MilchbergGraduate Program in Biophysics, University of Wisconsin-Madison, Madison, Wisconsin; Department of Biochemistry, University of Wisconsin-Madison, Madison, Wisconsin. Electronic address: milchberg@wisc.edu.
Owen A WarmuthGraduate Program in Biophysics, University of Wisconsin-Madison, Madison, Wisconsin; Department of Biochemistry, University of Wisconsin-Madison, Madison, Wisconsin.
Collin G BorcikDepartment of Biochemistry, University of Wisconsin-Madison, Madison, Wisconsin.
Dhruva D DhavaleDepartment of Neurology and Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, Missouri.
Elizabeth R WrightDepartment of Biochemistry, University of Wisconsin-Madison, Madison, Wisconsin; Cryo-Electron Microscopy Research Center, University of Wisconsin-Madison, Madison, Wisconsin; Midwest Center for Cryo-Electron Tomography, Department of Biochemistry, University of Wisconsin-Madison, Madison, Wisconsin; Morgridge Institute for Research, Madison, Wisconsin.
Paul T KotzbauerDepartment of Neurology and Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, Missouri.
Chad M RienstraDepartment of Biochemistry, University of Wisconsin-Madison, Madison, Wisconsin; Morgridge Institute for Research, Madison, Wisconsin; National Magnetic Resonance Facility at Madison, University of Wisconsin-Madison, Madison, Wisconsin; Department of Chemistry, University of Wisconsin-Madison, Madison, Wisconsin. Electronic address: crienstra@wisc.edu.

Funding

Technologies for Solid-State NMR Data CollectionP41GM136463 · NIGMS · UNIVERSITY OF WISCONSIN-MADISON · PI WESTLER, WILLIAM MILO · 2021 to 2025
$6.4M
Structural Biology of Alpha-Synuclein in Lewy Body DementiaRF1NS110436 · NINDS · WASHINGTON UNIVERSITY · PI KOTZBAUER, PAUL T, RIENSTRA, CHAD M · 2023 to 2023
$4.2M
Predoctoral Training in Molecular BiophysicsT32GM130550 · NIGMS · UNIVERSITY OF WISCONSIN-MADISON · PI SENES, ALESSANDRO · 2019 to 2023
$1.5M
Structural Biology and Biophysics of Alpha-Synuclein Fibrils by Solid-State NMRF32GM149118 · NIGMS · UNIVERSITY OF WISCONSIN-MADISON · PI BORCIK, COLLIN GRIFFIN · 2023 to 2024
$143k
NIGMS NIH HHS F32 GM149118NIGMS NIH HHS P41 GM136463NIGMS NIH HHS T32 GM130550NINDS NIH HHS RF1 NS110436
6 · The paper itself

Abstract

The accumulation of alpha-synuclein (Asyn) fibrils is the defining pathologic feature in Parkinson's disease, Lewy body dementia, and multiple system atrophy. As such, the process of Asyn fibril formation has been an important research area and fibrils themselves have become attractive targets for disease diagnosis and therapeutic intervention. Due to the presence of mixed populations of fibrillar proteins associated with neurodegenerative diseases in brain tissue, high-resolution structures of Asyn fibrils are essential for the design of high-specificity imaging and therapeutic agents. Approximately 100 high-resolution solid-state NMR spectroscopy and cryoelectron microscopy structures of Asyn fibrils have been deposited to the Protein Databank; intriguingly there is significant polymorphism among them. Understanding the molecular makeup and characteristic features of each structural polymorph can determine conserved structural motifs that can be used as templates to design ligands with high specificity for clinical use. Utilizing standard alignment tools and density-based clustering approaches, we objectively classify fibril structures by tertiary structure type. We find that 84% of the structures cluster into two polymorph classes. Within each class, additional subtle variations are observed, which position side chains in specific, conserved orientations, well poised as druggable targets. Furthermore, we find that the conserved structural motifs associated with each class are found in all but one published Asyn fibril structure. We consider these classifications and conserved motifs in the context of disease-relevant fibril structures and offer a perspective on the utility of in vitro fibrils as substrates for drug development and models for disease pathogenesis.

Indexed as

alpha-SynucleinAmyloidAmino Acid SequenceCluster AnalysisHumansModels, Molecularalpha-SynucleinAmyloid

Identifiers

PMID41404791
PMCPMC12414693

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.